Mastek Limited (MASTEK) Earnings Call Transcript & Summary

October 26, 2026

National Stock Exchange of India IN Information Technology IT Services earnings 64 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to the Mastek Limited Q2 FY27 earnings call. Today’s session starts with a presentation from the Mastek management team, and after that we’ll move into a Q&A segment. At this point I’ll turn the conference over to Mr. Niraj Khemka. Mr. Niraj, the floor is yours.

Niraj Khemka

executive
#2

Thanks, Melissa. Hi everybody, and welcome to the Q2 FY27 earnings call for Mastek Limited. Joining us on today's call are Mr. Umang Nahata, our CEO, and Mr. Deepak Kedia, our CFO. During this call, we will be making some statements that are forward-looking and that may carry a number of risks and uncertainties. Every forward-looking statement we make here is based on information currently available to management, and the company does not undertake to update any forward-looking statement that might be made during this call. On that point, a full disclosure has been included in the investor presentation as well as the press release. We consider that as read. With that, I'll hand the call over to you, Umang.

Umang Nahata

executive
#3

Good morning, everyone, and thank you, Niraj. To start off, a very good morning to all of you, and I appreciate everyone joining the call early today. So we're looking forward to a healthy interaction with all of you over the next one hour. Our Q2 performance has been a pretty healthy one and very close to expectations in terms of most of the parameters. Our — just 1 second. From a revenue standpoint, we had a very healthy growth of 2.4% quarter on quarter in constant currency terms. The revenue numbers landed at INR107.3 million for Q2. The EBITDA performance landed at 14.4%, which was around 96 basis points below quarter one, largely on account of salary hike, and we will discuss the details later in the call. Our order backlog, 12-month order backlog, grew by 2.2% year-on-year. There was some softness in the order book, and we'll talk about that also as we go forward. In the call. Overall, from a performance standpoint, I'll initially describe the performance from a geo standpoint. We'll then really spend time talking about how are we transforming Mastek into an AI-native organization and some of the really interesting stuff that is going on there. And we'll later pass the call to Deepak to explain more the financial performance in detail.

Umang Nahata

executive
#4

Now, regarding how we performed geographically, from the UK perspective, Q2 was a really strong quarter. We actually posted revenue growth of 4.1% in that quarter. Financial services remains a very strong subsector within the UK business. Our financial services grew by more than 16% in the quarter, and we keep seeing solid, healthy momentum in that sector. Public sector, which is our biggest sector in the UK, Europe geography, remains stable. We saw decent growth in public sector, supported both by some growth momentum and by higher working days in the last quarter. Healthcare and life sciences, which was a key driver and remains a key growth driver for us, is still lagging behind in the quarter's performance, primarily because of some right-shifting in project starts, as well as some order book. That said, I'm happy to report that some of these orders that were right-shifted have been concluded after the close of the quarter, and we expect the numbers to start improving as we move forward in H2. The other important development from a UK-Europe point of view is the opening up of a new front, which is around energy and utilities.

Umang Nahata

executive
#5

We’re glad to share that we have secured 3 new frameworks in energy and utilities, and we’ve also begun winning new contracts under those frameworks. That mainly fits with our approach of targeting sectors that purchase the way the public sector does but run themselves like, you know, a private-sector or privately held organization. And that has let us open a new front in energy and utility as well. We remain focused on the same approach of pursuing arm’s-length bodies that buy in the manner of public-sector-type organizations. As we move through the year, we’ll report on progress regarding how the energy and utilities sector is really developing as we go forward. Last but not least, the UK also had a change of Prime Minister, you know, in the last quarter. As the, you know, new ministers take office, there is a, you know, we expect—and we are monitoring any policy change or any direction, if there is any, from them. At present it appears that although healthcare will stay a priority, social care could be another area of significant focus for the government. And we are working to make sure we align back with the policies. The new government’s budgets are going to be announced any time this week, and we are watching developments there closely.

Umang Nahata

executive
#6

Until a number of these activities take place, several contracts that were meant to be decided have either been paused or, you know, called off and would be — these belong to the pipeline, the orders sitting in the pipeline, and would, you know, hopefully be relaunched once budgets get finalized, which made for a softer quarter where the order book is concerned. That applies to our UK business in Q2. Turning now to North America, that region keeps showing very strong deal momentum, and once again this quarter we posted a very positive order book. As a matter of fact, comparing our total order backlog for that geography year on year, it has increased by over 50%. These order bookings are both in terms of, you know, a focus on key verticals, which center on healthcare, life sciences, retail, and manufacturing. But plenty of AI-native transformation deals are also taking place in that geography, and we'll discuss some of them on the slides that follow as I move ahead. From an APAC and Middle East standpoint specifically, as all of you know, market uncertainty persists. As a matter of fact, it grows more stringent as we move ahead. While in Q2 we had some of the, you know, long-standing contracts get signed, and hence a decent revenue bounce back there.

Umang Nahata

executive
#7

But the broader picture for the Middle East remains uncertain, and we're watching events closely—particularly what's unfolding in Saudi Arabia—while making sound, judicious decisions as we go forward. Now, as I move forward and explain our business through the most important forward-looking lens—namely, how Mastek is transforming itself into an AI-native organization—as I mentioned, our vision centers on transformative business and on making AI—making Mastek a leader in AI transformation within our selected focused verticals. That we operate in. Given that focus, we've taken 2 really significant new steps, new offerings we've been working on over the last few months and which launched this quarter. The first concerns healthcare and life sciences, where we've signed a highly strategic partnership with a company named Innovaccer. Innovaccer is a market leader in delivering contextual data across the healthcare and life sciences domain. And we'll be partnering with Innovaccer as one of their biggest partners globally to help transform healthcare life sciences businesses on the foundation of the contextual data platform that Innovaccer provides. We believe this partnership will prove very strategic in positioning Mastek and Innovaccer among the leading providers of AI transformation services in healthcare and life sciences.

Umang Nahata

executive
#8

On a global basis. The partnership has begun scaling up right away as well, which includes building a solid pipeline during the first quarter of its signature itself. The second key piece concerned services as software. Once again, this is a space Mastek has been developing behind the scenes. Drawing on our expertise in enterprise applications, particularly with Oracle and Salesforce, along with our robust engineering and data capabilities, we have now managed to bring all three together into a new offering that we call Services as Software. It fundamentally has two dimensions. It leans more toward process transformation, yet it can equally handle a great deal of substitution of conventional SaaS softwares through the new Services as Software solution. In fact, within Mastek we have moved our CRM software, moved our procurement software, moved our recruitment system and also our accounts payable and expenses systems onto this same model, delivering not only solid savings on our subscription cost but also enormous enhancement in how AI-native solutions get used and in improving business outcomes and quality of performance. As we bring these learnings to the market, we have already closed our first few deals on services or software, and we are witnessing strong momentum going forward.

Umang Nahata

executive
#9

Then the final segment of the area—what we refer to as AI foundation, covering governance and security roadmapping and so on—that's the third piece of the business, and it's also performing well. Cyber was a key element we felt we ought to bring into our AI foundation, and over the past few months we've been working on that, with some investments inside our public sector market. And once more, I'm delighted to say those investments have begun producing results. This quarter as well, we recorded our first few meaningful wins in the cyber for AI space, you know, within our public sector deals. Some of those deals I'll cover on the next slide. On the whole, our AI momentum remains very strong. Even this quarter, over 40% of our deals are AI deals. And those deals are genuinely helping to shape Mastek toward a future in which it becomes an AI data and AI organization—something we're doing not only for our customers but also by transforming Mastek internally, as I explained earlier. I'll now share some experiences of the kinds of deals we're seeing and some of the learnings that we are—the references that we are creating.

Umang Nahata

executive
#10

To give investors a clearer picture of the type of work we're doing. The first example is a senior care skilled nursing facility. This is a services-as-software deal out of North America, a multimillion-dollar transaction in which we're replacing the core SaaS platform at a skilled nursing facility and helping them build an AI-native SaaS platform that will feature contextual data alignment and is intended to deliver a significant business outcome for our client in that region. The second deal is a life sciences company, again in dental technologies. This one is also a North America deal, where we've applied AI-led productivity improvements to displace an incumbent. And it's a, you know, $10 million-plus transaction, another large deal for North America this quarter. In it, we're providing AI-led productivity solutions to the client to help them lower their cost of IT services while delivering more value to that particular organization. The third deal you see here is the UK central government deal. Now, this is the cybersecurity deal I mentioned earlier, where we're providing cyber solutions and cyber assurance for a public sector customer in the UK. Again, it's a multi-year contract, multimillion-dollar in setup, and it lets us deliver cyber assurance, specifically cyber assurance that even extends beyond the regular kinds of cyber activities, to our client.

Umang Nahata

executive
#11

In a similar vein, deal number four is another process transformation engagement, once again built on Oracle's platform. It's for a police department in the UK, and there we're providing a great many of the AI agentic solutions Oracle offers when it comes to process transformation for a UK police department. Beyond that, the methodology we apply to these fixed bid projects goes by the name Adopt AI, our platform for executing fixed bid projects from a process transformation perspective. There are a couple of additional deals. This one, too, is a managed services engagement. The following one is likewise about AI productivity, where we managed to displace an incumbent through a bold AI productivity offering, once more leveraging our Adopt AI platform, and we're delivering a substantial outcome-based managed services contract to that client. The final deal sits in APAC and the Middle East — it's The, again, providing healthcare and life sciences process transformation for a strategic healthcare partner in that region, where we're assisting them in modernizing their legacy application into an AI-native solution going forward. As you can see, these deals range across AI productivity, AI for transformation services and software, plus a few centered on AI foundation, which spans everything from cyber to governance, etc.

Umang Nahata

executive
#12

Every one of these agreements leaves us feeling strongly that the three main pillars of what we provide in AI — starting with AI transformation, moving to AI foundation, and then AI productivity — are each building solid momentum. And in certain instances, they aren’t just assisting us in securing net new business; in many instances they’re also helping us hand over outcome-based business contracts to our clients. Overall, the trajectory we sense is quite encouraging, and we are actively pushing ahead with turning Mastek into an AI-native organization. Having said that, I’ll hand things over to Deepak so he can walk through further specifics regarding the quarter’s financial performance.

Deepak Kedia

executive
#13

Thank you, Umang. I'd like to extend a very warm welcome to everyone joining the call, and I appreciate you taking the time to be with us for Mastek's earnings call at such an early hour. Before I move on to updates on the other metrics and a few key changes to the investor data sheet, I'll begin with a review of the quarter. For Q2, our revenue came in at $107.3 million, which represents a 2.4% increase sequentially, along with an operating EBITDA of 14.4%. Revenue on a constant currency basis grew a robust 2.4% quarter over quarter. In rupee terms, we surpassed four digits for the very first time, posting revenue of INR1,018.7 crore — that's 3.4% sequential growth and 8.3% Y-on-Y growth. PAT came in at INR105.7 crore, equal to 10.3% of total income. We ended the quarter with a 12-month backlog of $286.2 million, which is a 7.7% decline sequentially and 2.3% Y-on-Y growth in USD, and 10.4% in INR terms. The sequential drop reflects deferred start and slower consumption of new projects. Basic EPS was INR34.1, an 8.3% rise versus last year, while diluted EPS stood at ₹33.9, up 8.4% versus last year. EBITDA fell 100 bps quarter over quarter, driven by increments in ESOP, which had a 190 bps impact, partially offset by AI-led productivity efficiency and additional working days.

Deepak Kedia

executive
#14

During Q2, margins came in as expected. Our goal is to achieve an improvement of no less than 160 bps over the medium term. That said, how quickly we improve will partly hinge on macro and geopolitical conditions. The quarter included some exceptional items. We finished selling a property in Chennai, which generated a profit that shows up in exceptional items. That profit was offset by workforce restructuring costs stemming from AI-driven efficiencies and by writing off aged receivables on the books. These are one-time in nature. I'll now turn to the company's cash position. In Q2, we had another strong collections quarter, bringing in roughly $120 million from customers, which produced a DSO of 74, a reduction of 1 day. At 74 days, DSO ranks among the best in the industry, a reflection of our disciplined cash management and assertive collection efforts. It also gives us more flexibility for strategic decisions. Closing cash and investments, net of debt, stand at INR582.7 crore. In the quarter, we paid a dividend of INR50 crores along with loan repayment of about INR55 crores. Even so, we managed to add close to INR36 crore to net cash and investments.

Deepak Kedia

executive
#15

Moving along now to how we performed geographically and by industry. Each of the three regions expanded in sequence during Q1. The UK still holds a solid EBIT margin of 18%. North America wrapped up another quarter with a healthy order book—as Umang mentioned earlier—lifting its overall backlog by 7.8% quarter over quarter and 47.9% year over year. As Umang noted, our AI momentum carries on, and during this quarter we booked 53 orders that were AI deals, with nearly 45% of the total order book coming from AI deals. On the industry side, the public sector continues to demonstrate strength, up 6.1% sequentially, while the private sector—specifically financial services—grew 15.3% quarter over quarter. Utilization, trainees included, declined 0.8% sequentially, reflecting the investment we're making in domain resources. Let me now cover a few other business metrics. Yeah, we brought on 18 new customers this quarter, up from 13 in the prior quarter. Closing headcount stands at 4,810, a decrease of 87 stemming from workforce restructuring and a shift in our on-site offshore mix. Our trailing 12-month attrition rate is down—lower for a second straight quarter by 1.2%. Sorry for the interruption. Uh, our trailing 12-month attrition rate has fallen for a second consecutive quarter by 1.2%, going from 16.4% to 15.2%.

Deepak Kedia

executive
#16

Finally, I want to highlight a few particular modifications we've implemented in the fact sheet so that it reflects our performance more accurately. We've adjusted several items in the client data so the business is represented more meaningfully. These include active clients over the preceding 12 months, active clients during the quarter, Forbes 1000 clients, top 5 and top 10 clients, repeat business, and we've also made adjustments to employee metrics by segment along with employee metrics by type. With that said, I'll now turn the call over to the operator, who can open it up for Q&A. Thank you very much.

Operator

operator
#17

Thanks a lot. <<operator_script>> Our first question is from Amit Chandra at HDFC Securities. Amit, go ahead with your question.

Amit Chandra

analyst
#18

Can you hear me?

Umang Nahata

executive
#19

Absolutely, Amit.

Operator

operator
#20

Yes.

Umang Nahata

executive
#21

Sure, Amit.

Amit Chandra

analyst
#22

Yes. Yes, sir. Thank you for giving me the chance. My first question concerns the order book. Clearly, you said most of the deals we've been winning are AI-led. But, uh, and we've also been, uh, you know, demonstrating strong traction when it comes to deal wins in the US geography. So is the weakness, uh, in the, you know, order book largely driven by, you know, slower execution on the deals that we won, uh, you know, earlier? Or is it, uh, some, uh, sort of pressure we're seeing in the, uh, you know, some sort of pressure we're seeing in the UK, uh, you know, geography? And also regarding your, you know, the commentary that FY27 would be better versus FY26, where do we stand on that and, you know, some of the deals that we've won, what would it be like, what would be the ramp-up schedule for those deals? Thank you.

Umang Nahata

executive
#23

Thanks for that question, Amit. So looking at it from the order backlog angle, we’ve got two scenarios here. First, one of the big deals we closed in North America with the federal government during the last quarter — the launch of that particular deal has now been pushed back until after the midterm elections, and because of that, our backlog has right-shifted, along with the 12-month backlog figures. So that’s what moved some of the backlog there. And in a similar vein, there was another deal over in the UK where, well, we’ve already secured the contract, but once again, consumption is coming in slower than we had anticipated. We expect consumption to pick up around Q4. And so, in that case as well, we’ve adjusted the 12-month backlog in light of consumption running slower than anticipated. That said, we remain quite confident that we’ll be able to consume all of these orders, but the pace of consumption is definitely slower than expected. And as you pointed out, that’s among the reasons the 12-month backlog has shown a bit of softness this quarter. Uh, moving to the, uh, second part of the equation, Amit, regarding our forecast, uh, or our, you know, judgment that FY27 will be better than FY26, we continue to, uh, be optimistic that, uh, our H2 performance — there’s no reason for, uh, it to be slower.

Umang Nahata

executive
#24

At this point we're confident H2 should keep performing well. That said, some of what's happening in the Middle East is definitely concerning and somewhat out of hand and beyond control. And we've already observed a fairly significant drop in Middle East performance versus what we'd been hoping for. But right now the UK and US are clearly bridging that gap and thus letting us deliver what we need to. So that's where things stand currently. So from our position, we feel comfortable that FY27 will outperform FY26. But some of these geopolitical uncertainties exist and that's somewhat beyond our control. Broadly speaking, the AI-native transformation is another area we're trying to adjust and pivot the organization toward. Because those deals keep coming in consistently and the demand cycle on them, you know, is much stronger and much higher, while execution is also much faster and better.

Amit Chandra

analyst
#25

All right. And regarding some of the AI deals we've closed, are they originating with current customers, or do they come more from brand-new ones? Also, on deal size, where do you see that heading, since most of the ones you listed are smaller, project-type engagements? So when might we see some traction on larger deals, or annuity-style arrangements, on the AI side? And on the overall revenue mix, if you could share what total revenue from AI is and how AI is growing, Y-o-Y versus the non-AI portion, that would help us understand the mix.

Umang Nahata

executive
#26

Okay, Amit — regarding the size of AI deals, let me start with this: AI deals are arriving from brand-new customers as well as from our current ones. Among the examples I presented today, at least two were net new deals that wouldn’t exist without AI. So those are clearly net new additions. A number of them also involve existing customers, where we’re partnering with them to transform their operations or raise productivity inside their businesses. So activity is definitely strong on both fronts — net new business and existing-customer business. As for AI deal sizes, at present we’re generally seeing deals ranging from $500,000 to $5 million. A few are smaller still, though those tend to be starting points — an entry point might be lower — but the average of half a million to 5 million is what we’re seeing right now on these deals. The AI transformation-type deals, I think, will start small at first, but rather than a customer signing one big deal all at once, they’ll grow into larger engagements. Our expectation is that they’ll sign transformation in pieces, and we’ll keep evolving the business continuously.

Umang Nahata

executive
#27

So that's what we expect in terms of how these deals will progress. It may not arrive as a single big order, then again it will keep evolving and expanding into a steady, sizable, repeatable business inside the same account and the same project. When it comes to really big AI deals, the only place we see them is where we can do AI-led productivity takeout type of work. And we're pitching for those types of deals as well. We have a fair number of them in our pipeline right now, but we still need to go out, execute, and win some, you know, multimillion-dollar transactions. I gave you one example of the life sciences deal we closed, which was a $10 million-plus transaction. Again, an AI productivity type of deal that we were able to execute. So AI productivity, you know, type of takeouts are large, but AI transformative deals will still sit in the under-$5 million bucket that I mentioned. As for AI revenue and the sequential and consistent performance of AI, you know, from a revenue standpoint, we'll begin to outline and present those numbers starting next quarter and going forward.

Umang Nahata

executive
#28

That way, you'll have a clear picture of where those figures sit. But, uh, as we see it, they're already making up a significant percentage of our total revenue.

Amit Chandra

analyst
#29

All right, and, uh, you know, my final question concerns margins. Clearly margins have been trending lower, uh, so if you could, you know, give the, you know, breakdown regarding, uh, what actually caused that margin decline in terms of what the ESOP, uh, you know, ESOP expenses were plus, uh, you know, the effect of the wage hike. And you also referenced, uh, 160 bps of recovery over the medium term. So if you could lay out the bridge — like, you know, what is, uh, you know, what we need to like watch for regarding the margin trajectory. And also regarding margins across the various like geographies, is it, uh, uh, you know, that the margins in the UK geography where we operate, you know, at the higher end — in the high teens. Is there a risk that margins in the UK also come down because of the productivity benefits demand, and also the margin trajectory for the, you know, like US and the Middle East geography? Thank you.

Deepak Kedia

executive
#30

Hi Amit, this is Deepak, and I’ll field that one. I’ll address the questions piece by piece, and if I skip anything, just flag it and I’ll gladly fill in whatever’s missing. On the margin decline — that breaks into three components. A couple of them you’ve already pointed to. The first is increment, and the other is SOB. Together, those two account for a 190 bps hit. The second factor we’re observing in the business is essentially a shift in mix. By mix shift, I mean certain sizable projects with high margins have wound down, and projects with lower margins have taken their place — and the lower margin stemmed mainly from a sovereignty requirement and a security-cleared-resource requirement, largely within the UK territory. And we’ve recorded a margin decline in that specific segment. That works out to roughly 200 bps of impact. Now, we’ve also managed to generate considerable AI-driven efficiencies internally. And as you’ll notice — and I mentioned workforce restructuring cost as well on account of that — that has delivered an improvement of close to 200 bps.

Deepak Kedia

executive
#31

So we're looking at a drop of roughly 150 to 160 bps again. From the level we were at, which was the 16% mark. So that is essentially the main leverage. During the current quarter, we didn't see a meaningful forex impact, which is usually what happens. That's possibly a tailwind of about 20 bps that we received. As for where things go from here, we'll have to kind of return to what we definitely want to return to, that 16% mark. Now, the speed at which we can drive that will hinge on plenty of external factors. The one factor I mentioned, the one that has essentially pulled the margin down, is the onsite mix, where the ask for local security resources is definitely rising and localization is definitely rising, and we will have to deal with that. And that will call for a systematic change internally for us to essentially recover that. And, so there are plans in place internally. We have identified a few areas that we are working on to essentially improve, the margin. Now, in the short term to medium term, As I said, the speed will really hinge on how the macro factors move and whether there are any changes in the current policies or in the way the government is asking for security clearance source.

Deepak Kedia

executive
#32

As everyone is aware, roughly 60% or 65% of our business originates in the UK, and that is mainly T&M. So we will need to comply with the rules that the new UK government has put in place. When it comes to the US and the Middle East, we are certainly seeing margin improvement in both of those geographies. That starts in Q3 itself, and it should definitely help us win back some of the margin we lost in the UK because of the mix change. Amit, I hope that covers all of your questions. If I missed any, please let me know.

Amit Chandra

analyst
#33

No, no — that was actually useful, and thanks, and best of luck to you.

Operator

operator
#34

Thanks. Our following question is from Dipesh Mehta at Emkay Global.

Dipesh Mehta

analyst
#35

Thanks for giving me the chance. From a growth standpoint, I’d like to get a clearer picture: for the US — or even North America — it still looks fairly muted to me. We had expected growth to pick back up in that region. Could you help us see which vertical is causing the headwind there? BFSI appears to be performing well, while healthcare is where the softness sits. If possible, give us a geographic view of those 2 verticals and how each market is trending. The second point concerns AI — with some of the deals you mentioned around momentum and so on, can you give us a sense of whether you’re seeing deal sizes change after the POC or after the initial conversation and execution, and whether sizes are increasing from a subsequent-deal standpoint, plus what gross margin you typically earn on those deals once they move into subsequent execution? Thank you.

Umang Nahata

executive
#36

Thank you, Dipesh. Now regarding the North America business, as we've said in recent quarters, the momentum in the order book is clearly heading in the right direction. And H2 is the point where we predicted the turn would come, and we're holding to that forecast that the North America business will begin to show a meaningful turnaround from H2 where growth momentum is concerned. So all the groundwork we've laid over roughly the last year — from our order book to the team structure to these AI offerings, and so on — has helped us build a strong base, and we believe that starting in H2, you should see a meaningful turnaround in North America from a growth standpoint. Healthcare and life sciences will remain our strongest vertical in North America, not only in terms of traditional business, but our AI focus, as I mentioned, is also very high on healthcare and life sciences, including the Innovaccer partnership, which is driving good positive momentum in terms of pipeline on AI transformation deals for healthcare and life sciences in the geography. So that's from the North America standpoint. As far as the AI deals are concerned, your observation is right, especially the AI deals which start with POC or small use cases or transformation in one process area are leading into newer areas.

Umang Nahata

executive
#37

So in that way, when we deliver transformation in one process area, it opens up use cases for other areas to deliver transformation. Also, the potential for the solution to evolve is very, very high. And as the client sees benefit in the initial solution that we deliver to them, then there's an expanded scope for delivering similar kinds of outcomes or benefits in other areas of their business. So we continuously see that once an AI engagement starts in an account, it clearly evolves into a continuous engagement of delivering more and more solutions. And it's not like a one-time, one-project kind of situation. From a margin standpoint on AI businesses, the AI transformation or the AI foundation kind of deals are running with a good margin of 40+% gross margin, and sometimes even running north of 50+% gross margin kind of businesses. The AI productivity kind of deals are much more price aggressive, and we are clearly taking a very aggressive forward-looking three-year bet in terms of delivering anywhere between 35% to 60 to 70% productivity on, you know, some of our traditional IT services. And there in those deals, the margins are actually compressed. And it will take time before, you know, while we have upfront margin compression, but over a period of time we'll be able to improve margins on these, on these kinds of deals.

Umang Nahata

executive
#38

That's really where the margin story sits. So the emphasis is on shifting increasingly toward transformation-type work, which plays far more to Mastek's strengths — and is much sweeter for us — than simply competing on productivity, which is clearly a red ocean.

Dipesh Mehta

analyst
#39

Got it. And regarding the vertical picture specifically in North America plus the UK, if you could share some color on BFSI in particular and also healthcare — how did those two markets perform when it comes to their growth trajectory?

Umang Nahata

executive
#40

BFSI remains a robust vertical for us, as I mentioned. Much of that growth is driven by our UK and Europe operations, where traction has been genuinely strong. A lot of the engagement involves fairly modern data-related work — the sort of deals I highlighted a few quarters ago with Bank of England, Financial Conduct Authority, and several others. That deal momentum is holding up well. We're generating solid business value for those clients, which is why we keep expanding within those accounts. In North America's financial services sector, promising openings are appearing too. We've brought in a handful of interesting new logos there. Still, growing the financial services business across North America requires considerable effort — we remain at an early stage. Turning to healthcare and life sciences, our capabilities are very strong in North America, the UK, Europe, and also the Middle East and APAC. This ranks among our strongest verticals, and substantial focus and attention go into becoming an AI transformative partner for healthcare and life sciences.

Umang Nahata

executive
#41

A significant portion of what we're already handling in that vertical is AI transformation work, along with the Innovaccer partnership and some of those services or software offerings we deliver. All of that sits within the healthcare and life sciences vertical. And we feel quite confident about the healthcare and life sciences business overall — while it's been, uh, slow over the last two quarters, we're very confident it will bounce back and remain one of our strongest growth engines going forward.

Dipesh Mehta

analyst
#42

Got it. And I’m not sure if I missed this in what you said earlier, but the order book looks a bit softer this quarter. Do you have any thoughts on whether decision-making is being delayed, which might affect the quarterly order book figure, or could you say something about how we should think about the order book going forward?

Umang Nahata

executive
#43

Okay, so a few areas stand out. Take the Middle East market — order book performance there is still softer, as I mentioned. We did recover some numbers this quarter, but looking at the full year, we're running well behind plan, and we're still monitoring that market to see how things play out. On North America, I've been clear on this: order book performance remains strong. In the UK, what we saw — and it's still hard to pin down a pattern — is that some important orders got stalled during the quarter, ones we had hoped to get signed. The change in Prime Minister has brought a change of cabinet, and they're reevaluating their policy areas and focus as well. As I said, the budgets will be announced later this week. So once we have more clarity — and I'm sure the departments also need more clarity on focus areas and budget — we're confident the order book, or the momentum in public sector order booking, should correct as we move forward.

Umang Nahata

executive
#44

Another key area I wanted to raise is the large deal pipeline we're seeing, especially in the UK and Europe, and in North America as well — it keeps growing phenomenally. There's this trend toward consolidating business into bigger deals. And we're seeing a very healthy pipe of, you know, $100 million plus kinds of deals sitting in our pipeline, which will be adjudicated over the next six to nine months — some of which we have already submitted, some which we are going to submit over the course of next three months. So that's another important factor which can change the order backlog in a single transaction itself. It can impact the numbers sizably.

Dipesh Mehta

analyst
#45

Got it. Thanks.

Operator

operator
#46

And moving to our next question, which comes from Sushovon Nayak at Anand Rathi.

Sushovan Nayak

analyst
#47

I trust you can hear me clearly.

Umang Nahata

executive
#48

Yes, that's correct — it's you.

Sushovan Nayak

analyst
#49

Just one quick item regarding the horizontal split and Oracle implementation revenues. I believe they’re disclosing that, along with the data and AI revenue as a percentage of total. Is that something you can give a view on, or is it disclosable at this point? That’s the first one. And the other thing I just wanted to understand: could you give a bit more color on the order book, or the order backlog, that you provided by geography? How should we look at it given that the numbers also — I mean, even though order books are rising, revenues possibly aren’t translating. If you could provide some color on these two aspects, that would be helpful.

Umang Nahata

executive
#50

Thanks. Hi, Sushovon. Could you just say that first part of your question again so we can get it clearly?

Sushovan Nayak

analyst
#51

On that horizontal split — I believe in prior quarters you disclosed Oracle implementation revenues alongside data and AI revenues as a percentage. My sense is that this time around it wasn't disclosed. If you could give us some color on that, I'd appreciate it.

Umang Nahata

executive
#52

Right, so as I mentioned before, starting next quarter we're taking a hard look at how we ought to present our horizontal split, and we will definitely give a data AI sort of view of the organization. That's the direction we want to move the business in, and I'm sure it will matter both to us and to all of our analysts and investors when it comes to understanding growth and movement on that side of the business. So we'll offer that view going forward. Broadly speaking, I just missed that first part.

Sushovan Nayak

analyst
#53

My apologies — I missed the beginning of your opening comments. That's on me. Sorry.

Umang Nahata

executive
#54

Okay, no problem. What I was mentioning is that I've got a bit of a sore throat. Let me move in closer. So, as I said, our emphasis is on transforming and heading in an AI-native direction. Because of that, we'll be offering a separate split-off segment focused specifically on the data and AI part of our business. So we're restructuring our horizontal — you know, the overall performance from a horizontal standpoint — and starting next quarter we'll begin sharing that once more through a data and AI lens going forward, both in terms of — we've been providing the order book figures, but beginning next quarter we will also start sharing revenue and other details. Regarding the Oracle business, broadly speaking, the Oracle business keeps performing well. In fact, we have quite healthy net new traction with Oracle specifically in North America as well as in the UK and Europe. So Oracle net new traction remains strong. We're also seeing solid traction with Oracle, not just when it comes to delivering implementation services, which was always strong, but also in winning net new managed services, which are more AI-led.

Umang Nahata

executive
#55

You know, we also have an AI-driven offering that delivers productivity on Oracle managed services, and that one is drawing a solid pipeline as well.

Sushovan Nayak

analyst
#56

Absolutely, thanks.

Umang Nahata

executive
#57

My apologies, Sushovon — I didn't catch the final portion of what you asked. Could you take a look at it?

Sushovan Nayak

analyst
#58

I believe we also gave the order book this time broken out by geography — the executable order book by geography. How should we view that alongside revenue growth and the next 12-month executable order book? Basically, how do we interpret these figures by geography? That's what I was hoping to get clear on.

Umang Nahata

executive
#59

Right, so Sushovon, our aim is to show those figures as they reflect where we stand right now. That said, look, the 12-month order backlog is a judgment we make from the orders we've secured and what our client currently tells us can be executed over the coming 12 months. Months. The variability — and this is exactly what has kept the backlog from turning into revenue quickly — comes down to how fast the client actually consumes. With some clients, things differ, or consumption on their end slows down, and so the 12-month backlog shifts up or down depending on their consumption pattern. A good example is the $25 million deal we closed last quarter with the federal department in North America. We were hoping to ramp it up quickly, and every indication we had from the client pointed that way. But given where their internal situation stood regarding the elections and so on, they chose to delay the project's start until the midterm elections, and that wasn't anticipated.

Umang Nahata

executive
#60

So because the start has now been pushed back, that caused an adjustment to our 12-month backlog — we had to revise those 12-month backlog figures. The 12-month backlog number, then, serves as an indicator of where we see the business heading as of the date we share it. But there are factors that move, particularly around how quickly the client might consume some of this, and that shifts the indicator, or makes it differ from the plan you had laid out regarding the 12-month rate at which it should have been consumed.

Sushovan Nayak

analyst
#61

Got it. One quick follow-up on that: could we get a sense of the exact tenure of these deals broken out by geography? For instance, you've shared the order book for North America, the UK, and EMEA as well. So is that something you can do? Could we see what the average tenure of these orders would be by region, or would that be —

Umang Nahata

executive
#62

We may not have the precise specifics on the call at this moment, but what tends to happen is that deals come in quite a few varieties. Some businesses are fairly tenured. Take a lot of our business in the UK and Europe, for instance — those are three-year plus two-year, five-year kinds of deals. A lot of the public sector too, as well as healthcare, and even financial services. So they are, you know, so we think of a three-year tenure when it comes to the order book there. When it comes to North America, you know, the average tenure would be roughly 18 months to 24 months for these deals. Again, the project businesses can sometimes be shorter. But I'm giving you something like an average ballpark figure.

Sushovan Nayak

analyst
#63

Got it. And on the project businesses as a share of total revenues, I think that figure used to be around 40%. Are you seeing that mix shift more toward managed services and less toward project work? Can you give us some color on that?

Umang Nahata

executive
#64

It’s getting better. So it’s increasing. Uh, though not at a pace that would, you know, uh, really shift, uh, you know, anything in a major way. So it has clearly improved from 40 — it’s risen to 44, around 45, uh, at this point. And we’re watching it closely. We’re definitely steering more and more toward outcome-based as well as fixed-price contracts with our client wherever we can. That said, a big chunk of our business is UK public sector and, you know, UK healthcare, where the government still purchases via rate cards, so the figure doesn’t move much simply because of that. But if we’ve shifted the number from 40 to 45 despite the UK business, that means plenty of our other businesses are seeing a shift toward fixed-bid, outcome-based types of contracting. Okay,

Sushovan Nayak

analyst
#65

Apologies, Umang — what I meant here was mainly the project-based parts of the business, the ones with shorter tenure. So are you saying that, in effect, fixed bid and project can be treated as the same thing, or is there something I'm not getting?

Umang Nahata

executive
#66

No, it doesn't have to be identical, though a significant portion of our project business is certainly fixed bid—most of it, in fact. Certain managed services or long-term contracts also carry a fixed bid character, but yes, a large percentage of the project business is fixed bid.

Sushovan Nayak

analyst
#67

Thank you very much. Appreciate it.

Operator

operator
#68

Thanks. Our following question is from Pulkit Chawla, 360 ONE Capital Market.

Pulkit Chawla

analyst
#69

Hi there, thanks for taking my question. First, on the healthcare vertical: looking back over the last year, that vertical is down more than 25%. First, is a specific geography driving that softness? You also mentioned that some orders closed after the quarter ended. So do you expect that, you know, by Q3 we should be back on the sequential path? My second question concerns your move into the energy and utilities vertical. What actually prompted this move? I mean, earlier you talked about being somewhat focused on a few verticals. So why enter a new vertical now? And what is your strategy for expanding into this vertical? Third, could you say a bit about your top 5 and top 10 cohort? I believe it has been somewhat weaker over the last few quarters now. So is there a specific reason, or some specific clients that are somewhat soft? And fourth, for Deepak — Deepak, I think subcon costs have been fairly high at this point. Do you see it as more of a structural issue, and where do you really think it probably ends up finally?

Umang Nahata

executive
#70

Okay, so, and we’ll do our best. As for, uh, I went and missed that first question once more.

Deepak Kedia

executive
#71

Healthcare, at 25%. Right.

Umang Nahata

executive
#72

Right, right. So on the healthcare side — healthcare and life sciences — as I mentioned, the softness you're currently seeing comes mainly from our UK and Europe business, which had actually been growing quite strongly in healthcare last year. The cause of that softness is that most of the projects we carried out last year have now wrapped up their discovery or alpha phase of the business and are moving into beta, which essentially means getting ready for production-type development. And to do the beta work, there has to be recontracting on those orders. There's a timing gap between the alpha and discovery work finishing and the recontract for the beta work happening on those accounts. Some of that timing gap has run longer than we expected, you know, in terms of securing them. And this is more on the government side, you know, from a timing standpoint in terms of organizing those bids. And that's been one of the reasons. Second, we also saw a ramp-down in one of our traditional healthcare offshore accounts in the UK, which has also contributed to some of the slowness in the healthcare business, uh, in the UK context.

Umang Nahata

executive
#73

So, all in all, though — as I mentioned — most of these beta contracts are now at a point where some have already gone out to bid, and we're waiting on, or expecting, results in Q3 or, at the latest, early Q4. That's the point when we anticipate them beginning to ramp back up at high speed going forward. That said, as I mentioned, the healthcare life sciences business worldwide is ramping up quite nicely as well. The order book we hold in North America contains a large share of healthcare and life sciences, and we'll keep seeing solid traction there. Many of the AI transformation deals I referenced earlier also sit within the healthcare and life sciences space, so our overall view is that healthcare life sciences will return to not just matching its prior number but beating the other verticals from a Mastek standpoint. We're therefore fairly optimistic that healthcare life sciences — the dip we're currently seeing — is temporary in nature, and that we'll be able to recover and grow it more quickly. Now, when it comes to the E&U vertical: our focus was to go after organizations that purchase the way the public sector does, through frameworks and the RFP buying process, and to apply those same credentials and criteria.

Umang Nahata

executive
#74

And naturally, operating in a manner similar to arm’s-length organizations or those in the private sector—that is the very approach we used to secure financial services clients in the prior year. And we keep pursuing bids within that identical framework. The robust RFP and public sector framework capabilities we possess in the UK can readily be leveraged to target these segments. And that represents—it is the outcome of that business that we are genuinely witnessing in these emerging areas. So that is—that is why we pursued these energy and utility frameworks and evidently have secured them, secured 3 of those frameworks across the last, you know, 90 to 120 days, and are also beginning to secure contracts beneath these frameworks. Now that we have established a presence here and managed to achieve solid preliminary breakthroughs, we will persistently concentrate on and grow these particular accounts where we have—where we have achieved some robust early progress. Regarding the top five, top ten client scenario, Pulkit. Once more, a number of the top five, top ten likewise included these healthcare clients in the combination, and that is why you observe the equilibrium. Yet broadly speaking, the connection, the overall commercial resilience within these accounts remains highly favorable.

Deepak Kedia

executive
#75

Pulkit, I’ll take that final question you raised about subcon cost. Our subcon cost has historically run at roughly 18% to 20% of revenue, and even now it sits at exactly that level. I don’t expect those figures to rise meaningfully. That said, I should give you a bit more color on what’s happening in the UK, consistent with what Umang said earlier. There’s certainly a significant push in the UK from the current cabinet, or the minister, where they’re asking for greater localization and security-cleared resources. So for any resource needing a special or specific skill set and security clearance within certain durations, we might see a need to bring in subcon in the short term, eventually replaced by FTs. Given that particular ask, subcon costs may move up or down by about 1 percentage point. Over the long run, though, I don’t see subcon cost going extravagantly higher than today’s level, which is 20%.

Pulkit Chawla

analyst
#76

That’s great. Thanks a lot, Umang.

Operator

operator
#77

And moving on, our following question is from Hitaindra Pradhan at Maximal Capital.

Hitaindra Pradhan

analyst
#78

Yes, yes. Hello there. Can you hear me okay?

Umang Nahata

executive
#79

Yes, Hitaindra.

Hitaindra Pradhan

analyst
#80

Yeah, yeah, thanks for the chance. I just had one — I need one point clarified. So the — you mentioned the UK NHS renewal and, you know, that new data transformation kind of project last quarter. So I just wanted to get a sense of whether, you know, I realize it has been delayed, but, you know, is it included in the order book you've just referred to, or is it going to be, you know, something in H2?

Umang Nahata

executive
#81

That is an H2 event.

Hitaindra Pradhan

analyst
#82

And yes, if you could provide any detail regarding the renewal — since we're running a new data transformation-type project and you're simply waiting for that beta phase to begin — then as far as PCV goes, would it come in above the prior contract, or would it land along similar lines?

Umang Nahata

executive
#83

Right now, what we have in place is a bridge contract that carries us from today until the point when that big deal is finalized. As I mentioned, this bridge agreement is meant to cover us over the shorter horizon — roughly the next 6 months. However, the sizable contract we're in the process of bidding on and competing for is, you know, a deal worth more than 100 million pounds.

Hitaindra Pradhan

analyst
#84

Sure, that would add to the ACV we have right now, assuming we land that one.

Umang Nahata

executive
#85

Yeah, yeah, definitely.

Hitaindra Pradhan

analyst
#86

All right, thanks.

Operator

operator
#87

Thanks, everybody. Ladies and gentlemen, that concludes our Q and A session. I'll now turn the conference back to management for closing remarks. Over to you.

Umang Nahata

executive
#88

Thank you, and thanks to all of you for joining the call and for sharing your insightful questions. As I mentioned, this is an interesting moment to conduct business. Many things are moving away from traditional IT services toward modern AI-native solutioning and transformation. This is bringing about not just a shift in how solutions are built, but also a shift in the approach to running a business. There are many new offerings and a great deal of creativity, along with many new kinds of partnerships that we are evaluating. Our endeavor and vision is to transform Mastek into a leader in AI transformation within our focus verticals, and we are moving significantly in that direction, you know. We remain positive about our performance as we go forward, and we are really bullish that over the next few quarters, you know, we will have transformed Mastek into a leader in the market of the future. So with that, I will thank you once again, everybody, and I look forward to connecting with you next quarter.

Deepak Kedia

executive
#89

Thanks, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Mastek Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Mastek Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Mastek Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.